AmorChem l.p.

44 articles with AmorChem l.p.

• AmorChem Invests in the Work of Sidong Huang at McGill University Using a Novel Target to Address a SMARCA4-deficient Rare and Aggressive Form of Ovarian Cancer

  6/4/2020

  AmorChem Invests in the Work of Sidong Huang at McGill University Using a Novel Target to Address a SMARCA4-deficient Rare and Aggressive Form of Ovarian Cancer MONTREAL--( BUSINESS WIRE )-- AmorChem II L.P. (“AmorChem”) is proud to announce the closing of a new transaction with McGill University (“McGill”), focusing on the work of Dr. Sidong Huang and his collaborator, Dr. Martin Schmeing, from the Rosalind and Morris Goodman Cancer Research Centre. The

• AmorChem Invests in a Potential Treatment for Cerebral Amyloid Angiopathy and Alzheimer’s Disease

  6/4/2020

  AmorChem is proud to announce a new investment in a research program hailing from Université Laval and the Research Center of the Centre Hospitalier Universitaire de Québec. The venture capital fund identified the opportunity in close collaboration with SOVAR, a group active in the promotion of university research. Am

• Consortium Backs Netherton Syndrome Project From Sinai Health

  5/12/2020

  Toronto Innovation Acceleration Partners, Evotec SE and AmorChem II Fund L.P. are pleased to announce a $1.75M investment into a drug development project focused on a rare skin disease called Netherton Syndrome, that affects one in 200,000 newborns worldwide.

• AmorChem Invests in Novel Approach to Target Myc-driven Cancers

  2/12/2020

  AmorChem II is proud to announce the financing of a collaboration centered around c-Myc, a proto-oncogene implicated in over 50% of all human cancers.

• AmorChem Closes a First Transaction with the Université de Sherbrooke

  4/17/2019

  AmorChem is proud to announce a first investment at the Université de Sherbrooke.

• AmorChem’s 2019 KNOCK OUT Event: Meet the Contenders

  4/9/2019

  Back by popular demand, AmorChem, the innovative Quebec-based seed venture capital fund, is hosting the 5th edition of its KNOCK OUT Event.

• A New Corporate Image for AmorChem

  4/2/2019

  AmorChem, a leading venture fund dedicated to creating the next generation of biotech companies derived from academic research, introduced its rebranding this week.

• Announcement of the Heavyweights for the 5th edition of KNOCK OUT 2019

  3/8/2019

  Back by popular demand, AmorChem, the innovative Quebec-based seed venture capital fund, is hosting the 5thedition of its KNOCK OUTTM Event, a challenge where the Contenders, academic researchers selected by AmorChem, duke it out in the ring against a panel of Heavyweight champions in order to qualify for a $500,000 financing from AmorChem.

• AmorChem Reinforces Its Innate Immunity Franchise with an Investment in Checkpoint Control Target SRSF3

  2/11/2019

  AmorChem II is very proud to announce the financing of a new university project.

• AmorChem, KNOCK OUT Event, 5th round

  1/15/2019

  AmorChem is hosting its fifth KNOCK OUT Event during the 1st edition of the EFFERVERSCENCE conference, April 24th, 2019 in Montreal.

• AmorChem Invests in Groundbreaking RNA Technology

  1/14/2019

  AmorChem II is proud to announce the closing of its first financing of a university project.

• AmorChem Spins out Its Muco-Adhesive Nanoparticle Delivery Platform into MyX Therapeutics, with 450,000$ Seed Investment.

  12/17/2018

  This capital will allow MyX to clinch its first deals with commercial partners, targeting primarily ocular diseases in both animal and human health.

• Amorchem Selected for Investment by the Venture Capital Catalyst Initiative

  11/6/2018

  AmorChem was built through the vision and leadership of its two founders, Elizabeth Douville and Inès Holzbaur, making it one of the rare venture capital funds led by two women.

• 

  BioSpace Movers and Shakers Nov. 5

  11/5/2018

  Biopharma companies make key appointments to fill leadership positions. Let's take a look!

• AmorChem Announces the Composition of Its Scientific Advisory Committee

  3/2/2018

  AmorChem selected these highly qualified individuals because collectively, they offer an enviable array of diversified expertise and experience in lifesciences venture capital investment, drug discovery and pharmaceutical development.

• AmorChem l.p. Release: Company Spins Out Its SEMA 3A Technology Into Semathera, With 1M$ Seed Investment

  1/11/2017

• AmorChem l.p. Spins Out Its Usp15-Deubiquitinylation (Dub) Drug Discovery Platform Into Corbin Therapeutics, With A First 1M$ Seed Investment

  1/9/2017

• AmorChem l.p. Spins Out Its CD36 Technology Into Mperia Therapeutics, With 1M$ Series A Investment

  9/12/2016

• AmorChem l.p. Release: André-Dupont Prize Awarded To Mike Sapieha!

  10/6/2015

• AmorChem l.p. Invests In Projects At The Personalized Cancer Immunotherapy Program

  4/8/2015